<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Teams on BEHIND-MS</title>
    <link>https://www.behind-ms.eu/en/tags/teams/</link>
    <description>Recent content in Teams on BEHIND-MS</description>
    <generator>Hugo</generator>
    <language>en</language>
    <lastBuildDate>Tue, 21 Jul 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://www.behind-ms.eu/en/tags/teams/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Principal Investigator - German Cancer Research Center</title>
      <link>https://www.behind-ms.eu/en/teams/pi-dkfz/</link>
      <pubDate>Sun, 12 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/pi-dkfz/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project&lt;/h2&gt;&#xA;&lt;p&gt;The team will isolate and characterize the Epstein-Barr viral strains that infect patients with multiple sclerosis. It will also analyse the interactions between the virus, the immune system and the central nervous system.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members&lt;/h2&gt;&#xA;&lt;h3 id=&#34;henri-jacques-delecluse---lab-head&#34;&gt;Henri-Jacques Delecluse - Lab head&lt;/h3&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/Henri-Jacques-Delecluse.jpg&#34; alt=&#34;Henri-Jacques Delecluse&#34;&gt;&lt;/p&gt;&#xA;&lt;p&gt;Henri-Jacques studied Medicine at the University of Lille, France. He did a specialty in Pathology at the University of Lyon, France. He is head of division at the German Cancer Research Centre (DKFZ) and professor at the |University of Heidelberg since 2003. His research focuses on the genetic analysis of the Epstein-Barr virus functions and they lead to cancer development. More recently, Prof. Delecluse embarked on a new project that focuses on the interactions between the Epstein-Barr virus, the central nervous system and the immune system.&lt;/p&gt;</description>
    </item>
    <item>
      <title>CNR - Istituto dei Sistemi Complessi</title>
      <link>https://www.behind-ms.eu/en/teams/cnr/</link>
      <pubDate>Wed, 15 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/cnr/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;A crucial aspect will be devising a transformer-based AI model for TCR and EBV-specific epitopes&#xA;embeddings. Furthermore, implementing the data science platform and statistical modelling tools&#xA;will be an important aspect of the effort.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members:&lt;/h2&gt;&#xA;&lt;h3 id=&#34;alessandro-taloni--project-lead&#34;&gt;Alessandro Taloni – Project lead&lt;/h3&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/Alessandro-Taloni.jpg&#34; alt=&#34;Alessandro Taloni&#34;&gt;&lt;/p&gt;&#xA;&lt;p&gt;Alessandro Taloni earned his Physics degree from the University of Rome La Sapienza in 2002 and&#xA;completed his PhD in theoretical Physics at the University of Perugia in 2006. Since 2017, He has held&#xA;a permanent research position at CNR-ISC. His research interests span a wide range, including&#xA;material science, theory of elasticity, soft matter and statistical physics, with a focus on non-&#xA;equilibrium phenomena, diffusion in micro- &amp;amp; nano-environments and fractional and anomalous&#xA;diffusion. In biophysics He covered topics such as cancer physics, protein conformational dynamics&#xA;and diffusion in the cytoskeleton. In the last years He has engaged on Artificial Intelligence applied to&#xA;healthcare problems.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Fondazione Istituto Nazionale di Genetica Molecolare, Università degli studi di Milano, Dipartimento di Scienze Cliniche e di Comunità</title>
      <link>https://www.behind-ms.eu/en/teams/ingm/</link>
      <pubDate>Wed, 15 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/ingm/</guid>
      <description>&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/INGM-team.jpg&#34; alt=&#34;INGM Team&#34;&gt;&lt;/p&gt;&#xA;&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project&lt;/h2&gt;&#xA;&lt;p&gt;We will monitor polyclonal, and virus-specific regulatory and cytotoxic effector T-cells in patients and humanised mice, including cells recognising potentially MS-associated EBV-derived epitopes. In addition, we will try to identify virus-derived factors that induce adaptive regulatory T-cells from pro-inflammatory precursors.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members&lt;/h2&gt;&#xA;&lt;h3 id=&#34;jens-geginat---pi&#34;&gt;Jens Geginat - PI&lt;/h3&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/Jens-Geginat.jpg&#34; alt=&#34;Jens Geginat&#34;&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;From a recent congress in Davos (WIRM)&lt;/em&gt;&#xA;Jens Geginat obtained his Diploma in Biochemistry as well as his Ph.D at the Department of Chemistry of the Free University of Berlin in 1994 and 1999, respectively. He performed the experimental work of his Diploma at the Istituto Tumori at Genoa in Italy, and of his Ph.D at the Scientific Institute of San Raffaele in Milan, Italy. He then joined the lab of A. Lanzavecchia at the Basel Institute for Immunology in Switzerland, and moved in 2000 to the Institute for Research in Biomedicine in southern Switzerland.  In 2006, he was selected for a Junior Group Leader position at the Charité Medicine University and the German Rheumatology Research Centre headed by A. Radbruch in Berlin, Germany. Since 2009 he works as Principal Investigator at the Istituto Nazionale di Genetica Molecolare. In 2020 he was appointed also as Assistant Professor for General Pathology at the University of Milan. His research interest is mainly focussed on the role of T-cells that produce the anti-inflammatory cytokine IL-10 in a wide range of pathologies.&lt;/p&gt;</description>
    </item>
    <item>
      <title>German Cancer Research Center (DKFZ), HI-STEM - Institute for Stem Cell Technology</title>
      <link>https://www.behind-ms.eu/en/teams/dkfz/</link>
      <pubDate>Wed, 15 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/dkfz/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project&lt;/h2&gt;&#xA;&lt;p&gt;Our group&amp;rsquo;s expertise lies in the direct reprogramming of adult human cells into neural progenitors and the development of sophisticated protocols to generate a wide variety of neural tissues from these cells. In this project, using cells from MS patients, we will first generate a comprehensive bank of reprogrammed patient stem cells, a much-needed resource for both our project and other researchers in the field. We will then derive neural organoids from these stem cells, with a particular focus on modelling the niche that is predominantly affected in multiple sclerosis. Using these organoids, we will develop an acute MS neural injury model and perform transplants into prodromal MS mouse models, with the ultimate goal of understanding the underlying disease mechanisms and identifying new avenues for treatment.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Istituto Superiore di Sanità</title>
      <link>https://www.behind-ms.eu/en/teams/iss/</link>
      <pubDate>Wed, 15 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/iss/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project&lt;/h2&gt;&#xA;&lt;p&gt;The main goal of the project is to provide a deeper understanding of the complex interplay between Epstein-Barr Virus (EBV) and the host immune system in MS. ISS researchers will contribute by analysing EBV DNA load and viral and immune gene expression in the blood of People with MS and healthy donors, and will use their extensive neuropathological expertise to further investigate the possible link between EBV infection and immune activation in post-mortem brain tissue donated by People with MS.&lt;/p&gt;</description>
    </item>
    <item>
      <title>University of Münster, University Hospital, Department of Neurology with Institute of Translational Neurology</title>
      <link>https://www.behind-ms.eu/en/teams/wwu/</link>
      <pubDate>Wed, 15 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/wwu/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;An important aspect of this project is to investigate immune control mechanisms of EBV infection in larger, well-curated cohorts of people with MS:&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members:&lt;/h2&gt;&#xA;&lt;h3 id=&#34;prof-jan-lünemann--project-lead&#34;&gt;Prof. Jan Lünemann – Project lead&lt;/h3&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/Jan-Lunemann.jpg&#34; alt=&#34;Jan Lünemann&#34;&gt;&lt;/p&gt;&#xA;&lt;p&gt;Jan D. Lünemann is Full Professor of Neurology at the University of Münster, Germany. He is coordinating of one of the largest European Multiple Sclerosis (MS) and Neuroimmunology Outpatient Clinics and Clinical Trial Centers. Dr. Lünemann received his medical degree at Humboldt University and his residency training in the Department of Neurology at the Charité University Hospital, both in Berlin, Germany. He received his postdoctoral training with focus on Cellular Immunology at the U.S. National Institutes of Health (Bethesda, MD) and at the Rockefeller University in New York. Before his tenure in Münster, he was Assistant Professor and Head of the Department of Neuroinflammation at the Institute of Experimental Immunology, University of Zürich, and Senior Consultant at the Departments of Neurology, University Hospitals of Basel and Zürich, Switzerland. Dr. Lünemann received the Human Immunology Award from the Irvington Institute for Immunological Research and the Dana Foundation, New York, and the Siegenthaler Scientific Award for Medical Sciences from the University of Zürich. He is Fellow of the American Neurological Association (ANA) and the European Academy of Neurology (EAN), member of the EAN Scientific Panels on MS and Neuroimmunology and Co-Chair of the German Task Force for Hematopoietic Stem Cell Transplantation and Cell-Based Therapies in MS. His research focuses on understanding the immunology and improving immunotherapies for people with MS and other autoimmune diseases.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Clinical Neuroimmuology – Multiple Sclerosis Centre of Catalonia</title>
      <link>https://www.behind-ms.eu/en/teams/vhir/</link>
      <pubDate>Sun, 12 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/vhir/</guid>
      <description>&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/vhir-pic.jpg&#34; alt=&#34;VHIR&#34;&gt;&lt;/p&gt;&#xA;&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;VHIR will recruit 20 treatment-naïve patients with relapsing-remitting (N=18) and primary progressive (N=2) MS who produce EBV in throat washes, and 20 sex/age-matched controls. Blood samples and throat washes will be sent to several consortium partners. VHIR will also investigate the interactions between EBV and cytomegalovirus by performing single-cell RNA sequencing in peripheral blood cells from MS patients at the time of the first demyelinating event.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Erasmus MC – MS Center ErasMS</title>
      <link>https://www.behind-ms.eu/en/teams/emc-ems/</link>
      <pubDate>Sun, 12 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/emc-ems/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;We have workflows up and running that will be used to profile B and T cells isolated from fresh post-mortem MS brain tissues at the single cell level. For this, scRNA-seq (including TCR/BCR-seq) and 33-40 color-based spectral flow cytometry will be used. Furthermore, our team has advanced culture assays to mimic T cell-dependent/independent human (T-bet/CXCR3+) B-cell differentiation (primary and recall responses) in vitro.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members:&lt;/h2&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/EMC-EMS-team.jpg&#34; alt=&#34;EMC EMS Team&#34;&gt;&lt;/p&gt;</description>
    </item>
    <item>
      <title>Institute of Experimental Immunology, University of Zurich</title>
      <link>https://www.behind-ms.eu/en/teams/uzh/</link>
      <pubDate>Sun, 12 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/uzh/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project&lt;/h2&gt;&#xA;&lt;p&gt;Mice with reconstituted human immune systems (Humanized Mice) are used to model EBV infection and how it influences CNS infiltration as well as neuroaxonal damage, prodromal signs of MS.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members&lt;/h2&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/UZH-team.jpg&#34; alt=&#34;UZH Team&#34;&gt;&lt;/p&gt;&#xA;&lt;h3 id=&#34;christian-münz-phd--professor-and-co-director-of-the-institute-of-experimental-immunology&#34;&gt;Christian Münz, PhD – Professor and Co-Director of the Institute of Experimental Immunology&lt;/h3&gt;&#xA;&lt;p&gt;Christian Münz has been trained in immunology at the German Cancer Research Institute in Heidelberg, Germany, the University of Tübingen, Germany, and the Rockefeller University in New York, USA. He became Assistant Professor and Head of Laboratory at the Rockefeller University in 2003. In 2008 he was recruited as Associate Professor and Co-Director of the Institute of Experimental Immunology to the University of Zürich, Switzerland, and became Full Professor in 2015. Since 2010 he is also Visiting Professor at the Imperial College in London, UK. In 2006 he received the Burroughs Welcome Fund Investigators in Pathogenesis of Infectious Disease Award for his studies on antigen processing via macroautophagy, and in 2012 the Sobek Award for his studies on the association of Epstein Barr virus (EBV) infection with multiple sclerosis (MS). He is an expert in EBV specific immune control and humanized mice as preclinical models for human oncogenic gamma-herpesvirus infections, and has published more than 300 peer reviewed papers and review articles on these topics.&lt;/p&gt;</description>
    </item>
    <item>
      <title>European Multiple Sclerosis Platform</title>
      <link>https://www.behind-ms.eu/en/teams/emsp/</link>
      <pubDate>Sat, 11 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/emsp/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;EMSP is leading on the Communication and Dissemination Work Package to ensure that complex research notions that the research consortium partners are leading on is translated in a user-friendly, more accessible manner to provide updates to people with MS, their caregivers and patient organisations. This will include, but not limited to, leading on the development of communication material such brochures and videos with project updates, updating content on the project’s website and social media platforms dedicated to people with MS, and organisation of livestreamed discussions to bring in together people with MS and researchers and healthcare professionals. EMSP will also support consortium partners to know more on effective engagement of people with MS, this way this practice becomes more common among researchers. In other work packages, EMSP will share the relevant, unique sections of this research with its member organisations to further disseminate the reach of the research to interested people with MS.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Università di Verona</title>
      <link>https://www.behind-ms.eu/en/teams/univr/</link>
      <pubDate>Fri, 10 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/univr/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;Neuropathological and molecular characterization of the intrathecal immune response against EBV and of the linked brain pathology in post-mortem multiple sclerosis cases.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members&lt;/h2&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/UNIVR-team.jpg&#34; alt=&#34;UNIVR team&#34;&gt;&lt;/p&gt;&#xA;&lt;h3 id=&#34;roberta-magliozzi---unit-head&#34;&gt;Roberta Magliozzi - Unit Head&lt;/h3&gt;&#xA;&lt;p&gt;Roberta Magliozzi is an Associate Professor at the Dept of Neuroscience, Biomedicine and Movement Sciences of University of Verona. She graduated in Biological Sciences at the University of Rome &amp;ldquo;La Sapienza&amp;rdquo; (1999) and then obtained a doctorate in Neuroimmunology at the Imperial College London (2009), where she maintains an honorary position of Senior Lecturer. Since the beginning, her main research interest is to better understand the immunopathological mechanisms and the inflammatory response and the role of ectopic tertiary lymphoid-like structures in the meningeal compartment of post-mortem MS tissues and to characterize the linked cortical grey matter damage and the intrathecal inflammation generated in the cerebrospinal fluid. She has contributed to 75 peer reviewed publications (h-index:35) also assessing the role of EBV as possible trigger of multiple sclerosis chronic inflammation. She recently achieved also a RFA-grant from the National MS Society (NMSS) “Meningeal lymphoid-like structures as secret EBV hideout in multiple sclerosis” involving spatial transcriptomic analysis of EBV gene expression combined with human gene expression in the leptomeninges of post-mortem MS cases.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Helmholtz Munich</title>
      <link>https://www.behind-ms.eu/en/teams/hmgu/</link>
      <pubDate>Mon, 26 Aug 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/hmgu/</guid>
      <description>&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/en/teams/hmgu/img/hmgu-1.jpg&#34; alt=&#34;HMGU&#34;&gt;&lt;/p&gt;&#xA;&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;We seek to profile the Epstein-Barr virus-specific antigen repertoire recognized by T and B cells, determine their epitope specificity and possible cross-reactivities with brain antigens.&lt;/p&gt;&#xA;&lt;h2 id=&#34;team-members&#34;&gt;Team Members:&lt;/h2&gt;&#xA;&lt;h3 id=&#34;josef-mautner---unit-head&#34;&gt;Josef Mautner - Unit Head&lt;/h3&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/Josef-Mautner.jpg&#34; alt=&#34;Josef Mautner&#34;&gt;&lt;/p&gt;&#xA;&lt;p&gt;Josef Mautner studied pharmacy and obtained his PhD from the University of Regensburg, Germany.  His research focus is on mechanisms of antigen presentation and on T and B cell responses against viruses and tumours.&lt;/p&gt;</description>
    </item>
    <item>
      <title>CING</title>
      <link>https://www.behind-ms.eu/en/teams/cing/</link>
      <pubDate>Tue, 20 May 2025 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/cing/</guid>
      <description>&lt;h2 id=&#34;contribution-to-the-project&#34;&gt;Contribution to the project:&lt;/h2&gt;&#xA;&lt;p&gt;The Cyprus Institute of Neurology and Genetics (CING) contributes to the BEHIND-MS consortium by applying network-based integrative bioinformatics to explore how EBV-host imbalances drive MS onset and progression. This includes using single-cell RNA sequencing to analyze immune cell interactions in blood and CSF, constructing protein-protein interaction networks between viral, host, and MS-related proteins, and incorporating key redox signaling pathways. The project also applies network-based pathway analysis and computational drug repurposing to identify potential treatments, and will deliver an interactive computational atlas combining multi-level data and expert knowledge on the immune system, EBV, and MS.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Publications</title>
      <link>https://www.behind-ms.eu/en/research/publications/</link>
      <pubDate>Tue, 21 Jul 2026 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/research/publications/</guid>
      <description>&lt;h2 id=&#34;behind-ms-research-publications&#34;&gt;BEHIND-MS Research publications&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&#xA;&lt;h3 id=&#34;proinflammatory-epsteinbarr-virus-antibody-functions-track-with-disease-activity-in-multiple-sclerosis&#34;&gt;Proinflammatory Epstein–Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis&lt;/h3&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Behrens M., Comabella M, Münz, C., Lünemann JD.  et al. &lt;a href=&#34;https://doi.org/10.1002/ana.78285&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Proinflammatory Epstein–Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis&lt;/a&gt;&#xA; Ann Neurol., (2026)&lt;/em&gt;&lt;/p&gt;&#xA;&lt;p&gt;We compared antibodies against Epstein-Barr virus (EBV) in people with multiple sclerosis (MS) and healthy individuals. We found that EBNA1-specific antibodies (a certain EBV protein) in MS patients were more inflammatory and better at activating immune responses that can damage tissue, and these antibodies were linked to periods when the disease was more active. This suggests that the immune response to EBV may not just be a marker of MS but could also help drive disease activity.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Reviews</title>
      <link>https://www.behind-ms.eu/en/research/reviews/</link>
      <pubDate>Tue, 21 Jul 2026 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/research/reviews/</guid>
      <description>&lt;h2 id=&#34;behind-ms-review-articles&#34;&gt;BEHIND-MS Review articles&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&#xA;&lt;h3 id=&#34;epsteinbarr-virus-and-multiple-sclerosis-from-associations-to-mechanisms-to-potential-therapies&#34;&gt;Epstein–Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies&lt;/h3&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Lünemann JD., Münz, C. &lt;a href=&#34;https://doi.org/10.1016/S1474-4422%2826%2900177-8&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Epstein–Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies&lt;/a&gt;&#xA; The Lancet Neurology, vol. 25, iss. 8, pp 755-763, (2026)&lt;/em&gt;&lt;/p&gt;&#xA;&lt;p&gt;This review discusses the potential mechanisms driving the association between EBV and MS before delving deeper into potential therapeutic interventions arising from this association. Strategies currently under investigation include prophylactic and therapeutic vaccines; allogeneic cytotoxic T lymphocytes specific for Epstein–Barr virus and designed to eliminate virus-infected cells; antibody-based and chimeric antigen receptor T-cell-based therapies targeting B-cell subsets induced by Epstein–Barr virus and migrate into the CNS; and conventional antiviral treatments. Together, these approaches might open new perspectives for both prevention and treatment of multiple sclerosis.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Advisory board</title>
      <link>https://www.behind-ms.eu/en/teams/board/</link>
      <pubDate>Fri, 10 May 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/teams/board/</guid>
      <description>&lt;p&gt;The consortium will be supported by an external advisory board (EAB) which consists of scientific experts, an expert patient nominated by E.M.S.P. and a representant from industry.&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Ms. Jana Hlavacova, expert patient group, E.M.S.P.&lt;/li&gt;&#xA;&lt;li&gt;Professor Maria Masucci, Karolinska institute, Stockholm, Sweden&lt;/li&gt;&#xA;&lt;li&gt;Dr. Francesca Aloisi, Retired former employee of the Istituto Superiore di Sanità, Rome, Italy&lt;/li&gt;&#xA;&lt;li&gt;Christopher Oelkrug Director Business Development at Advanced Clinical&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;jana-hlaváčová&#34;&gt;Jana Hlaváčová&lt;/h2&gt;&#xA;&lt;p&gt;&lt;img src=&#34;https://www.behind-ms.eu/img/teams/Jana-Hlavacova.jpg&#34; alt=&#34;Jana Hlaváčová&#34;&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Jana Hlaváčová&lt;/strong&gt; brings to the advisory board a lived patient experience and expertise of a pan-European patient organisation – European Multiple Sclerosis Platform (EMSP). Diagnosed with Multiple Sclerosis (MS) at age 24, Jana has been actively involved with the EMSP since 2015, initially through the Young People&amp;rsquo;s Network, later serving in the Executive Committee (2015–2022) and interim CEO (Sept 2022–May 2023). She continues to contribute as EMSP&amp;rsquo;s External Policy Advisor. Jana works at the Ministry of Health of the Czech Republic, where she co-founded a patient involvement agenda and currently focuses on healthcare policy areas including clinical trials, health technology assessment, healthcare workforce and relating innovative technology applications. She was part of COVID-19 crisis management teams and coordinated provision of Czech humanitarian aid in medicinal products to Ukraine shortly after the Russian invasion. Jana has a legal background and has previously held positions dedicated to human rights on national and international level.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Strengthening Scientific Synergies in the BEHIND-MS Consortium</title>
      <link>https://www.behind-ms.eu/en/news/2025-07-16/</link>
      <pubDate>Wed, 16 Jul 2025 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/2025-07-16/</guid>
      <description>&lt;h2 id=&#34;strengthening-scientific-synergies-in-the-behind-ms-consortium-partner-visits-in-zurich-and-rotterdam&#34;&gt;Strengthening Scientific Synergies in the BEHIND-MS Consortium: Partner Visits in Zurich and Rotterdam&lt;/h2&gt;&#xA;&lt;p&gt;In collaborative research, face-to-face interactions often bring an added dimension of depth and momentum that emails and online meetings cannot fully replace. Within the BEHIND-MS consortium, recent exchange visits between partners have reinforced the value of close coordination, shared learning, and mutual inspiration across institutions.&lt;/p&gt;&#xA;&lt;p&gt;This year, two key visits took place between partners leading Work Packages 2 and 4 of the BEHIND-MS project: the University of Zurich’s Institute of Experimental Immunology, co-directed by &lt;strong&gt;Prof. Christian Münz&lt;/strong&gt;, and the MS Center ErasMS at Erasmus MC, led by &lt;strong&gt;Prof. Marvin van Luijn&lt;/strong&gt;.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Mystery Solved Project 2025</title>
      <link>https://www.behind-ms.eu/en/news/2025-05-26/</link>
      <pubDate>Mon, 26 May 2025 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/2025-05-26/</guid>
      <description>&lt;h2 id=&#34;mystery-solved-project-2025-advancing-the-understanding-of-ebv-and-ms&#34;&gt;Mystery Solved Project 2025: Advancing the Understanding of EBV and MS&lt;/h2&gt;&#xA;&lt;p&gt;On 23–24 May 2025, the &lt;a href=&#34;https://www.charcot-ms.org/about&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;European Charcot Foundation&lt;/a&gt;&#xA; and the &lt;a href=&#34;https://www.charcot-ms.org/conferences/mystery-solved-project-2025&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Mystery Solved Project (MSP)&lt;/a&gt;&#xA; hosted a high-level virtual conference bringing together global experts in multiple sclerosis (MS), Epstein-Barr virus (EBV), and immunology. This landmark event offered a unique platform for interdisciplinary exchange, exploring the complex interplay between viral infection, immune system dysfunction, and neurodegenerative disease.&#xA;&lt;img src=&#34;https://www.behind-ms.eu/en/news/2025-05-26/img/MysterySolved2025-600x410.jpg&#34; alt=&#34;Search for EBV&#34;&gt;&lt;/p&gt;&#xA;&lt;h3 id=&#34;the-role-of-epstein-barr-virus-in-multiple-sclerosis&#34;&gt;The Role of Epstein-Barr Virus in Multiple Sclerosis&lt;/h3&gt;&#xA;&lt;p&gt;Recent scientific breakthroughs have increasingly pointed to EBV as a key environmental factor in the development and progression of MS. The virus’s capacity to infect B cells and evade immune surveillance has placed it at the center of neuroimmunological research, particularly for its suspected role in initiating autoimmune processes targeting the central nervous system (CNS).&lt;/p&gt;</description>
    </item>
    <item>
      <title>Welcome Cyprus Institute of Neurology and Genetics</title>
      <link>https://www.behind-ms.eu/en/news/welcomecing/</link>
      <pubDate>Thu, 15 May 2025 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/welcomecing/</guid>
      <description>&lt;p&gt;We are pleased to announce that the &lt;a href=&#34;https://www.cing.ac.cy/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Cyprus Institute of Neurology and Genetics (CING)&lt;/a&gt;&#xA; has officially joined the BEHIND-MS consortium. As a leading research and medical center in Cyprus with a strong international presence, CING brings a wealth of experience in clinical services, cutting-edge research, and education — all dedicated to improving lives.&lt;/p&gt;&#xA;&lt;p&gt;CING’s contribution to the BEHIND-MS project is led by &lt;strong&gt;Professor George Spyrou&lt;/strong&gt;, Head of the Bioinformatics Department - &lt;strong&gt;CING Bioinformatics Department (C-BIG)&lt;/strong&gt;. His team  specializes in developing and applying advanced computational methods to interpret complex biological data, uncover disease mechanisms and identify promising treatment strategies, with a focus on personalized and precision medicine.&lt;/p&gt;</description>
    </item>
    <item>
      <title>External Advisory Board Meeting</title>
      <link>https://www.behind-ms.eu/en/news/eab-2025-02/</link>
      <pubDate>Wed, 12 Feb 2025 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/eab-2025-02/</guid>
      <description>&lt;h2 id=&#34;behind-ms-consortium-advancing-together-with-expert-guidance&#34;&gt;BEHIND-MS Consortium: Advancing together with expert guidance&lt;/h2&gt;&#xA;&lt;p&gt;The BEHIND-MS Consortium continues to push the boundaries of multiple sclerosis (MS) research, working collaboratively to uncover the intricate role of Epstein-Barr Virus (EBV) in the onset and progression of MS.&lt;/p&gt;&#xA;&lt;p&gt;Kickstarting 2025, the consortium held an online session with our esteemed &lt;a href=&#34;https://www.behind-ms.eu/en/teams/board/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;External Advisory Board (EAB)&lt;/a&gt;&#xA; to reflect on the valuable feedback received during our Annual Meeting in Heidelberg.&lt;/p&gt;&#xA;&lt;h2 id=&#34;integrating-expert-insights&#34;&gt;Integrating Expert Insights&lt;/h2&gt;&#xA;&lt;p&gt;During this session, we meticulously reviewed each Work Package to ensure that every recommendation from our EAB is thoughtfully considered and integrated into our ongoing research. The expertise and guidance of our advisory board are instrumental in refining our approach and maximizing the impact of our work.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Role of EBV in Autoimmunity and Multiple Sclerosis</title>
      <link>https://www.behind-ms.eu/en/news/2024-08-27/</link>
      <pubDate>Tue, 27 Aug 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/2024-08-27/</guid>
      <description>&lt;h2 id=&#34;new-insights-at-the-3rd-joint-ebv-kshv-international-symposium-a-dive-into-the-role-of-ebv-in-autoimmunity-and-multiple-sclerosis&#34;&gt;New Insights at the 3rd Joint EBV-KSHV International Symposium: A Dive into the Role of EBV in Autoimmunity and Multiple Sclerosis&lt;/h2&gt;&#xA;&lt;p&gt;The 3rd Joint Meeting of the &lt;a href=&#34;https://ebv.ksvirus.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;International Symposium on EBV, KSHV - Related Agents and Diseases&lt;/a&gt;&#xA; was held in Boston from June 29th to July 3rd, 2024. This marked a significant gathering for researchers working on Epstein-Barr Virus (EBV), Kaposi Sarcoma Herpes Virus (KSHV), and other gamma herpesviruses to come together and share their most recent and exciting results. This year’s meeting was also the occasion to celebrate the 60th anniversary of the discovery of EBV and the 40th anniversary of the discovery of KSHV, while also paying tribute to the life and the work of Sir Anthony Epstein, a pioneering virologist who co-discovered EBV and whose legacy continues to inspire the scientific community.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Jan Lünemann visits DKFZ</title>
      <link>https://www.behind-ms.eu/en/news/2024-07-22-jan/</link>
      <pubDate>Mon, 22 Jul 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/2024-07-22-jan/</guid>
      <description>&lt;p&gt;Jan Lünemann, Professor of Neurology at the University Hospital Münster, visited colleagues and collaborators at the DKFZ in Heidelberg on the 24th of May 2024.&lt;/p&gt;&#xA;&lt;p&gt;As a member of the BEHIND-MS consortium, he wanted not only to update his consortium partners and other interested members of the scientific public on his recent work on the role of EBV infection for MS, but also take this opportunity for scientific exchange and strengthening the collaboration links between BEHIND-MS partners.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Background</title>
      <link>https://www.behind-ms.eu/en/news/background/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/background/</guid>
      <description>&lt;p&gt;As the BEHIND-MS group, we want to &lt;strong&gt;understand&lt;/strong&gt; through this project how EBV leads or&#xA;connects to MS. We have gathered a team of experts to study how the virus interacts with the&#xA;immune system in the blood and brain of people with MS. We will also look at how genes play a&#xA;role in MS. We will be making a model of MS in the laboratory using cells from people with MS,&#xA;which will help us understand how MS works. We will also create a model of early MS in animals&#xA;to help test new treatments.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Kickoff</title>
      <link>https://www.behind-ms.eu/en/news/kick-off/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/kick-off/</guid>
      <description>&lt;p&gt;Today the project kick-off meeting was held with all teams participating.&lt;/p&gt;&#xA;&lt;p&gt;Henri-Jacques Delecluse welcomed all participants and gave a short overview of the current topics.&lt;/p&gt;&#xA;&lt;p&gt;&lt;figure&gt;&lt;img src=&#34;https://www.behind-ms.eu/en/news/kick-off/img/kick-off-screenshot-450-192.png&#34;&#xA;    alt=&#34;Virtual kick-off meeting&#34;&gt;&lt;figcaption&gt;&#xA;      &lt;p&gt;Virtual kick-off meeting&lt;/p&gt;&#xA;    &lt;/figcaption&gt;&#xA;&lt;/figure&gt;&#xA;&#xA;Monica Ensini gave an overview of &lt;a href=&#34;https://hadea.ec.europa.eu/index_en&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;HaDEA&lt;/a&gt;&#xA; and Horizon Europe project implementation.&#xA;Since BEHIND-MS has already been approved and is ongoing, any budget cuts will not affect the project.&lt;/p&gt;&#xA;&lt;p&gt;Lisa Greiner gave an overview of matters from the Grant Office, including payments, reports and audits.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Research</title>
      <link>https://www.behind-ms.eu/en/news/research/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/research/</guid>
      <description>&lt;p&gt;The BEHIND-MS project is a joint European research effort whose goal is to unravel the contribution of the Epstein-Barr virus to the pathogenesis of Multiple Sclerosis.&lt;/p&gt;&#xA;&lt;h2 id=&#34;multiple-sclerosis-ms&#34;&gt;Multiple Sclerosis (MS)&lt;/h2&gt;&#xA;&lt;p&gt;is the most frequent neuroinflammatory disease that is typically diagnosed in young adults, most frequently females. Despite new treatments that slow the progression of the disease, patients with MS frequently evolve towards major disability and neurodegeneration.&lt;/p&gt;&#xA;&lt;p&gt;The pathogenesis of MS is controversially debated and remains globally enshrouded in mystery, but the recent discovery that infection with the Epstein-Barr virus (EBV) is a major risk factor for MS development will radically change research avenues in the field.&#xA;&lt;em&gt;The project started 1st of December 2023 with a duration of 5 years.&lt;/em&gt;&lt;/p&gt;</description>
    </item>
    <item>
      <title>First Announcement</title>
      <link>https://www.behind-ms.eu/en/news/first-announcement/</link>
      <pubDate>Fri, 01 Dec 2023 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/first-announcement/</guid>
      <description>&lt;p&gt;See also: &lt;a href=&#34;https://www.eurekalert.org/news-releases/1010132&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;eurekalert&lt;/a&gt;&#xA;&lt;/p&gt;&#xA;&lt;h2 id=&#34;background&#34;&gt;Background&lt;/h2&gt;&#xA;&lt;p&gt;The progression of multiple sclerosis (MS) can usually be slowed down with&#xA;medication, but a cure is currently not possible. It is now established that Epstein-Barr&#xA;virus is involved in the development of MS. However, it is not known how the&#xA;pathogen triggers the disease.&lt;/p&gt;&#xA;&lt;h2 id=&#34;eu-funding&#34;&gt;EU funding&lt;/h2&gt;&#xA;&lt;p&gt;The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe programme, which&#xA;aims to clarify these associations in order to identify specific biomarkers and targeted&#xA;therapeutic approaches. The consortium, led by the German Cancer Research Center,&#xA;will receive 7.1 million euros over a period of five years.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
